Can you screen for cross-reactivity with Non-Human Primates (NHP)?

Yes. We highly recommend including Cynomolgus or Rhesus orthologs in the screening strategy to ensure your leads are ready for translational animal models.

How do you address Fc effector function in these antibodies?

For transplant antagonists, we can engineer the Fc region (e.g., LALA mutations) during IgG conversion to silence effector functions like ADCC/CDC, preventing unwanted cell depletion.

What functional assays are available for validation?

We offer Mixed Lymphocyte Reactions (MLR), T-cell proliferation assays, cytokine release profiling, and receptor-ligand blockade assays.

Allograft Rejection Specific Antibody Discovery Service by Premade Library

Screening Services Workflow Premade Libraries Cases Related Services Why Choose Us? FAQ

Developing next-generation therapeutics for allograft rejection requires a delicate balance: potent suppression of pathogenic alloreactivity without the broad toxicity of conventional immunosuppressants. Creative Biolabs combines massive premade human antibody libraries (up to 10¹¹ diversity) with specialized functional screening strategies designed to identify highly specific co-stimulation blockers and cytokine modulators. We deliver fully human, developable antibody candidates.

Get Started. Request Your Quote Today

Anti-Allograft Rejection-Specific Antibody Discovery

The gold standard for preventing allograft rejection is shifting from broad systemic immunosuppression to targeted biologic modulation. However, discovering antibodies that effectively induce tolerance while remaining safe for chronic use is challenging. Creative Biolabs' Premade Antibody Library Service addresses this by leveraging massive repertoires to find rare antagonists against co-stimulatory molecules and inflammatory cytokines. Our integrated platform moves beyond simple binding, prioritizing candidates that functionally inhibit T-cell activation.

Our phage and yeast display platforms are tuned to navigate our premier libraries with surgical precision. We utilize competitive panning strategies to identify potent blockers of receptor-ligand interactions (e.g., immune checkpoints) and integrate early functional triage. By systematically eliminating non-specific binders and prioritizing clones that perform in lymphocyte suppression assays, we deliver candidates that survive the rigors of downstream development.

Launch Your Project. Get a Quote.

How We Work

Inputs

Target, MoA goal (antagonist/blocker), species cross-reactivity (Human/Cyno), assay endpoints.

Workflow

Fig.1 Antigen Design. (Creative Biolabs AI)

Antigen Design

Fig.2 Enrichment (Panning). (Creative Biolabs AI)

Enrichment (Panning)

Fig.3 Clone Screening. (Creative Biolabs AI)

Clone Screening

Fig.4 Functional Selection. (Creative Biolabs AI)

Functional Selection

Fig.5 Sequence Analytics. (Creative Biolabs AI)

Sequence Analytics

Fig.6 IgG Conversion. (Creative Biolabs AI)

IgG Conversion

Deliverables

Ranked functional binders, epitope bins, sequence families, IgG mini-panel, full report.

Share Your Target Detail. Get Pricing.

Ready-to-Screen Antibody Libraries

Human Camel Llama Alpaca Humanized V_HH

Antibody Library ID	Display Technology	Library Format	Library Size
HuScL-6 ☆Highly Recommended	pIII-fusion, Phagemid Phage Display	Naïve scFv	2.1×10¹¹
HuScL-3S	pIII-fusion, Phagemid Phage Display	Semi-synthetic scFv	>1.0×10¹¹
HuFabL-4	pIII-fusion, Phagemid Phage Display	Naïve Fab	1.9×10¹⁰
HuFabssL-1	pIII-fusion, Phagemid Phage Display	Naïve & synthetic Fab	1.8×10¹⁰

Find the Perfect Library for Your Target

Case Study: High-Diversity Libraries, High-Impact Outcomes

High-Selectivity Discovery of Antibodies Targeting a Non-Classical MHC Immune Tolerance Molecule

Objective

In transplant immunology and precision oncology, targeting Peptide-MHC (pMHC) complexes represents the pinnacle of epitope discrimination. These TCR-like antibodies must navigate extreme structural homology, as the difference between a Mutant Target pMHC and its Wild-Type (WT) Control often resides in a single amino acid side chain.
The primary challenge is not just finding a binder, but identifying clones with a distinct Differential Binding Profile that is capable of prioritizing the mutant neoantigen over the endogenous native complex despite the >99% structural identity of the pMHC scaffold.

Strategic Approach

To solve this high-homology challenge, our team implemented a High-Stringency Subtractive Selection workflow using our Premade Human scFv Library.
Pre-discovery Consultancy: We provided strategic guidance on antigen stabilization to ensure the pMHC complex maintained its native conformation.

Exhaustive Pre-absorption

Parallel Negative Selection

High-Stringency Enrichment

Key Results & Validation Data

1. High-Resolution Monoclonal Identification
Following four rounds of high-stringency biopanning, an intensive monoclonal screening campaign was executed to isolate rare clones capable of fine-tuned epitope discrimination.
Fig.7 Graph illustrating the library screening outcomes. (Creative Biolabs Original)

Fig.7 Graph illustrating the library screening outcomes. (Creative Biolabs Original)

Through Monoclonal Phage ELISA, we identified candidates that exhibited the preferential binding profile for the mutant pMHC over the wild-type counterpart.
DNA sequencing confirmed three unique scFv sequences with distinct CDR architectures. These leads demonstrate the platform's ability to resolve subtle structural variations caused by a single-residue substitution within the MHC-binding groove.

2. Soluble Expression & Differential Binding Verification
To ensure that the observed selectivity was intrinsic to the antibody's paratope and not an artifact of multivalent phage avidity, the lead clones were expressed as soluble proteins in the E. coli periplasm. Fig.8 Graph displaying the soluble ELISA results. (Creative Biolabs Original)

Fig.8 Graph displaying the soluble ELISA results. (Creative Biolabs Original)

Soluble ELISA confirmed a definitive Affinity Gap. All three unique clones maintained the enhanced binding signals for the mutant pMHC compared to the WT control.

3. Pilot Production & Functional Bioactivity
The lead scFv candidates were transitioned into a eukaryotic expression system for conversion into full-length human IgG1 antibodies, facilitating downstream therapeutic evaluation.
Fig.9 Graph displaying the binding activity results. (Creative Biolabs Original)

Fig.9 Graph displaying the binding activity results. (Creative Biolabs Original)

Dose-response ELISA demonstrated that the preferential binding to the mutant target identified during the discovery phase was successfully preserved in the full-length IgG format.

Technical Support

Upstream Strategy

We provided critical guidance on negative selection design, which was the decisive factor in distinguishing the mutant target from the wild-type homolog.

Downstream Engineering

Following discovery, we supported the client through eukaryotic expression optimization and purification, ensuring the transition from a sequence to a high-purity antibody was seamless and efficient.

Get an End-to-End Plan & Quote

Related Services

Fig.10 Anti-Disease-specific Target Antibody Discovery. (Creative Biolabs Authorized)

Anti-tumor-specific Target Antibody Discovery

Anti-infectious disease-specific Antibody Discovery

Anti-inflammation disease-specific Antibody Discovery

Anti-autoimmune disorder-specific Antibody Discovery

Talk to a Scientist

Why Choose Us?

Targeted Immunosuppression

Our screening platform is optimized to find functional blockers and modulators, not just binders, enabling precise control of immune pathways.

Low Immunogenicity by Design

By utilizing fully human libraries and validated frameworks, we minimize the risk of ADA responses which is essential for lifelong transplant therapies.

Functional-First Decisions

Integrated functional assays ensure that selected leads have the biological potency required for in vivo efficacy.

Library–Screening Synergy

Our 10¹¹ diversity libraries paired with competitive panning yield high-affinity candidates even against difficult, conserved receptors.

Weeks, Not Months

Our engineered workflow bypasses immunization, delivering functional IgG leads in a fraction of the time required for hybridoma methods.

Radical Transparency

You receive full sequence data, functional datasets, and raw files, empowering your team to make data-driven decisions.

Customize Your Package. Get Pricing.

Ready to move fast? Creative Biolabs will scope your target, advise on best library and protocol, and get screening up and running as soon as possible.

FAQ

Can you screen for cross-reactivity with Non-Human Primates (NHP)?
Yes. We highly recommend including Cynomolgus or Rhesus orthologs in the screening strategy to ensure your leads are ready for translational animal models.
How do you address Fc effector function in these antibodies?
For transplant antagonists, we can engineer the Fc region (e.g., LALA mutations) during IgG conversion to silence effector functions like ADCC/CDC, preventing unwanted cell depletion.
What functional assays are available for validation?
We offer Mixed Lymphocyte Reactions (MLR), T-cell proliferation assays, cytokine release profiling, and receptor-ligand blockade assays.

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

	USA: Europe: Germany:
	Call us at: USA: UK: Germany:
	Fax:
	Email: